LGA-score essentially corresponds to the number of large genomic alterations [18] modulated by penalties (subtracted if the genomic features known to be associated with nonHRD, such as CCNE1 or ERBB2 amplification, were detected) and/or bonuses (added mainly if the CNA pattern is consistent with near-diploid tumor genomic content). The gene discussed is ERBB2; the disease is neoplasm.